Application Nr Approved Date Route Status External Links
NDA210656 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Daurismo Is Indicated, In Combination With Low-Dose Cytarabine, For The Treatment Of Newly-Diagnosed Acute Myeloid Leukemia (Aml) In Adult Patients Who Are ≥75 Years Old Or Who Have Comorbidities That Preclude Use Of Intensive Induction Chemotherapy. Daurismo Is A Hedgehog Pathway Inhibitor Indicated, In Combination With Low-Dose Cytarabine, For The Treatment Of Newly-Diagnosed Acute Myeloid Leukemia (Aml) In Adult Patients Who Are ≥75 Years Old Or Who Have Comorbidities That Preclude Use Of Intensive Induction Chemotherapy. ( 1 )

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Glasdegib GLASDEGIB ZINC68251434

Comments